Ziihera

Pharma

After trial fail, Teravance is bought out by Zymeworks for $929M

Four months after Theravance Biopharma signaled it was up for sale, the Dublin-based company has agreed to be bought out by Zymeworks for $929 million.

Kevin Dunleavy Jun 29, 2026 11:30am

Jazz touts Ziihera as HER2 agent of choice in stomach cancer

Jan 6, 2026 3:25pm

pay deal hand over cash licensing transaction money

Zymeworks pivots to become 'royalty-driven' drugmaker

Nov 18, 2025 8:25am

Jazz reviewing M&A deal options of 'various sizes,' CFO says

Feb 26, 2025 11:08am

Jazz hunts for new CEO as longtime chief Cozadd eyes retirement

Dec 17, 2024 10:49am

Jazz's HER2 bispecific snags FDA nod to rival Enhertu

Nov 21, 2024 7:53am